David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments

Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies have become the largest class of biopharmaceuticals with over 80 antibodies currently approved for a variety of disease indications. The development of smaller, antigen binding antibody fragments, derived fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bates, Adam, Power, Christine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640713/
https://www.ncbi.nlm.nih.gov/pubmed/31544834
http://dx.doi.org/10.3390/antib8020028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640713/
https://www.ncbi.nlm.nih.gov/pubmed/31544834
http://dx.doi.org/10.3390/antib8020028

Ejemplares similares